GlassScriptPhysician profile
David J Choi
NPI 1285864702
$3,536.90
in general payments reported to CMS, 2019-2025
27 companies · $449 in 2025
The $449 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $134 · 2021: $186 · 2022: $456 · 2023: $820 · 2024: $1,224 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,059 · Long Term Medical Supply Or Device Loan: $433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,059.35 |
| Long Term Medical Supply Or Device Loan | $433.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $1,321.77 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Angiodynamics, INC. | $658.77 | 2023-2024 | Auryon Laser System 100-120 Vac, Auryon Laser System 100-120 Vac |
| Abbott Laboratories | $198.16 | 2022-2025 | Xience Skypoint, Amplatzer Amulet, Esprit |
| Cook Medical LLC | $137.28 | 2020-2021 | |
| Endologix LLC | $133.37 | 2019 | |
| Penumbra, INC. | $125.00 | 2022 | |
| Esperion Therapeutics, INC. | $121.57 | 2020 | |
| Biotronik INC. | $103.51 | 2023 | Orsiro Mission |
| Abiomed | $101.72 | 2024-2025 | Impella |
| Merck Sharp & Dohme LLC | $88.77 | 2021-2023 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $87.98 | 2019-2023 | Brilinta |
| Novartis Pharmaceuticals Corporation | $76.10 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $41.51 | 2022-2024 | Lifevest |
| Boston Scientific Corporation | $37.31 | 2022-2025 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.02 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $31.53 | 2023-2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $31.32 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $29.97 | 2022-2024 | Opsumit, Uptravi |
| Amgen INC. | $27.65 | 2019-2022 | |
| Canon Medical Systems USA, INC. | $27.37 | 2019 | |
| Philips North America LLC | $24.46 | 2025 | Coronary Other |
| Daiichi Sankyo INC. | $21.13 | 2023 | Injectafer |
| Novo Nordisk INC | $20.67 | 2023 | Ozempic |
| E.R. Squibb & Sons, L.L.C. | $17.20 | 2023 | Eliquis |
| Medtronic Vascular, INC. | $16.56 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.26 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.